You just read:

Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring

News provided by

Orexigen Therapeutics, Inc.

Apr 04, 2011, 08:01 ET